. Author manuscript; available in PMC: 2023 Jun 21.

Published in final edited form as: J Am Acad Dermatol. 2023 Feb 2;88(5):1024–1032. doi: 10.1016/j.jaad.2022.12.048

Table IV.

Association of cirAE morphology with overall survival

Cutaneous morphology^*	Hazard ratio	95% CI	P value^†
Vitiligo	0.29	0.12, 0.71	.007^*
Acneiform eruption	0.34	0.13, 0.87	.025^*
Lichenoid eruption	0.51	0.36, 0.73	<.001^*
Psoriasiform eruption	0.52	0.33, 0.82	.005^*
Rash NOS	0.68	0.57, 0.81	<.001^*
Isolated pruritus without visible manifestation of rash	0.71	0.55, 0.91	.007^*
Eczematous eruption	0.71	0.50, 1.01	.056
Drug hypersensitivity NOS	0.79	0.52, 1.21	.3
Maculopapular eruption	0.82	0.66, 1.03	.084
Bullous eruption	0.87	0.45, 1.68	.7
Other cirAE morphologies	0.98	0.64, 1.50	>.9

CirAE, Cutaneous immune-related adverse event; NOS, not otherwise specified.

Each row corresponds to a separate multivariable time-varying Cox proportional hazards model for the association of cirAE morphology with overall survival by comparison to patients without cirAEs, adjusting for age at ICI initiation, gender, race, CCI, cancer type, ICI type, and year of ICI initiation.

^†

P values that remain significant after Benjamini-Hochberg multiple comparison adjustment are marked with an asterisk.